Growth Metrics

Gilead Sciences (GILD) Cash & Current Investments (2016 - 2026)

Gilead Sciences filings provide 17 years of Cash & Current Investments readings, the most recent being $7.6 billion for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 23.61% to $7.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.6 billion, a 23.61% decrease, with the full-year FY2025 number at $7.6 billion, down 23.61% from a year prior.
  • Cash & Current Investments hit $7.6 billion in Q4 2025 for Gilead Sciences, up from $7.3 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $10.0 billion in Q4 2024 to a low of $2.8 billion in Q2 2024.
  • Median Cash & Current Investments over the past 5 years was $6.1 billion (2022), compared with a mean of $6.2 billion.
  • Biggest five-year swings in Cash & Current Investments: plummeted 76.07% in 2021 and later skyrocketed 88.06% in 2025.
  • Gilead Sciences' Cash & Current Investments stood at $6.5 billion in 2021, then fell by 2.07% to $6.4 billion in 2022, then grew by 13.77% to $7.3 billion in 2023, then surged by 37.54% to $10.0 billion in 2024, then dropped by 23.61% to $7.6 billion in 2025.
  • The last three reported values for Cash & Current Investments were $7.6 billion (Q4 2025), $7.3 billion (Q3 2025), and $5.2 billion (Q2 2025) per Business Quant data.